ESMO scientific and educational resources on this topic
Recent medwireNews and resources from conferences are for ESMO Members only.
Tumour Sites: Haematological Malignancies
Leukaemia and Myeloma
Clinical Practice Guidelines
Latest ESMO videos
Featured medwireNews
Carfilzomib Combination Fails To Improve Newly Diagnosed Multiple Myeloma Outcomes
Cardiac Monitoring Need Highlighted For Non-Hodgkin’s Lymphoma Patients
Listeriosis Susceptibility Concern Raised For Daratumumab Treatment
Daratumumab Shows Clinical Benefit in Combination With Standard of Care in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
2-Year ZUMA-1 Results Add Support For Axicabtagene Ciloleucel In Refractory Large B-Cell Lymphoma
E-Learning
ESMO E-Learning: Open Questions in the Treatment of Follicular Lymphoma
ESMO E-Learning: Treatment of Multiple Myeloma Patients
ESMO E-Learning: Chronic Lymphocytic Leukaemia (CLL): State-of-the-art
ESMO E-Learning: Mantle Cell Lymphoma
ESMO E-Learning: Double-Hit Lymphomas
Meeting resources
Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: A randomized, open-label trial
Presenter: Atul Sharma
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
Presenter: Yan Xie
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with HIV-related lymphoma
Presenter: Marina Popova
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Role of baseline PET SUVmax in predicting early progression in follicular lymphoma (FL): A single-center retrospective analysis
Presenter: Ayushi Chauhan
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL
Presenter: Eleni Tholouli
Session: Mini Oral - Haematological malignancies
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.